Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease

期刊论文
出版模式：

开放获取
发表日期：

2024年9月9日

查看全文

Andrea Pilotto,
Nicholas J. Ashton,
Alessandro Lupini,
Beatrice Battaglio,
Cinzia Zatti,
Chiara Trasciatti,
Stefano Gipponi,
Elisabetta Cottini,
Ilaria Grossi,
Alessandro Salvi,
Giuseppina de Petro,
Marina Pizzi,
Antonio Canale,
Kaj Blennow,
Henrik Zetterberg,
Alessandro Padovani

摘要

Introduction

The prognostic role of plasma neurofilament light chain (NfL), phospho-tau, beta-amyloid, and GFAP is still debated in Parkinson’s disease (PD).

Methods

Plasma p-tau181, p-tau231, Aβ1-40, Aβ1-42, GFAP, and NfL were measured by SIMOA in 136 PD with 2.9 + 1.7 years of follow-up and 76 controls. Differences in plasma levels between controls and PD and their correlation with clinical severity and progression rates were evaluated using linear regression analyses.

Results

Patients exhibited similar distribution of plasma biomarkers but higher P-tau181, P-tau231 and lower Aβ1-42 compared with controls. NfL and GFAP correlated with baseline motor and non-motor severity measures. At follow-up, NfL emerged as the best predictor of progression with marginal effect of GFAP and p-tau181 adjusting for age, sex, disease duration, and baseline motor severity.

Conclusion

The present findings confirmed plasma NfL as best predictor of progression in PD, with a marginal role of p-tau181 and GFAP.